Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.